Table 3 Univariate analysis of PrEP acceptability according to facilitators and obstacles, Benin
|  | Average ± standard deviation | Acceptability | ||||
|---|---|---|---|---|---|---|
Yes (5) N = 143 | No (4 + 3 + 2 + 1) N = 257 | ORa | CI 95% | p | ||
n(%) | n(%) | |||||
Facilitators | ||||||
 Not having to pay for PrEP | 4.48 ± 0.58 |  |  |  |  |  |
  5 |  | 116 (81.1) | 88(34.3) | 9.45 | 3.36–26.62 | <.0001 |
  (4 + 3 + 2 + 1) |  | 27 (18.9) | 169(65.7) | 1 |  |  |
 Access to free HIV testing | 4.46 ± 0.49 |  |  |  |  |  |
  5 |  | 104(72.7) | 82(31.9) | 7.19 | 2.90–17.81 | <.0001 |
  (4 + 3 + 2 + 1) |  | 39(27.3) | 175(68.1) | 1 |  |  |
 Access to free healthcare/sexual life supervision | 4.45 ± 0.51 |  |  |  |  |  |
  5 |  | 98(68.5) | 84(32.7) | 5.13 | 2.24–11.73 | 0.001 |
  (4 + 3 + 2 + 1) |  | 45(31.5) | 173(67.3) | 1 |  |  |
 Access to individual support and support around the use of PrEP | 4.40 ± 0.57 |  |  |  |  |  |
  5 |  | 100(69.9) | 74(28.8) | 7.04 | 2.65–18.67 | <.0001 |
  (4 + 3 + 2 + 1) |  | 43(30.1) | 183(71.2) | 1 |  |  |
 Access to information on the use of PrEP | 4.61 ± 0.53 |  |  |  |  |  |
  5 |  | 115(80.4) | 138(53.7) | 4.65 | 1.32–16.37 | 0.01 |
  (4 + 3 + 2 + 1) |  | 28(19.6) | 119(46.3) | 1 |  |  |
 Access to support or counseling about my sexual life | 4.38 ± 0.63 |  |  |  |  |  |
  5 |  | 99(69.2) | 74(28.8) | 4.41 | 1.80–10.79 | 0.001 |
  (4 + 3 + 2 + 1) |  | 44(30.8) | 183(71.2) | 1 |  |  |
 Not having to go to the casual doctor for the PrEP | 3.78 ± 0.98 |  |  |  |  |  |
  (5 + 4) |  | 113(79.1) | 192(74.7) | 1.02 | 0.37–2.82 | 0.95 |
  (3 + 2 + 1) |  | 30(20.9) | 65(25.3) | 1 |  |  |
 Access to group memberships information on PrEP use | 4.18 ± 0.72 |  |  |  |  |  |
  (5 + 4) |  | 130(90.9) | 241(93.8) | 0.53 | 0.21–1.31 | 0.17 |
  (3 + 2 + 1) |  | 13(9.1) | 16(6.2) | 1 |  |  |
 Drug availability | 4.80 ± 0.40 |  |  |  |  |  |
  5 |  | 134(93.7) | 190(73.9) | 9.97 | 1.73–57.32 | 0.01 |
  (4 + 3 + 2 + 1) |  | 9(6.3) | 67(26.1) | 1 |  |  |
 Drug accessibility at the level of MSM networks | 4.18 ± 1.01 |  |  |  |  |  |
  5 |  | 125(87.4) | 73(28.4) | 15.14 | 3.89–58.95 | <.0001 |
  (4 + 3 + 2 + 1) |  | 18(12.6) | 184(71.6) | 1 |  |  |
 Self-protection concern | 4.18 ± 0.86 |  |  |  |  |  |
  (5 + 4) |  | 126(88.1) | 207(80.5) | 1.16 | 0.25–5.32 | 0.84 |
  (3 + 2 + 1) |  | 17(11.9) | 50(19.5) | 1 |  |  |
 Possibilities of Multiple partnerships | 3.26 ± 1.12 |  |  |  |  |  |
  (5 + 4) |  | 93(65.0) | 80(31.1) | 1.78 | 0.56–5.63 | 0.32 |
  (3 + 2 + 1) |  | 50(35.0) | 177(68.89) | 1 |  |  |
 Lack of constraints during drug procurement | 4.35 ± 0.66 |  |  |  |  |  |
  (5 + 4) |  | 130(90.9) | 245(95.3) | 0.89 | 0.52–1.55 | 0.69 |
  (3 + 2 + 1) |  | 13(9.1) | 12(4.7) | 1 |  |  |
 Sex possibilities with HIV-Positive | 301 ± 1.03 |  |  |  |  |  |
  (5 + 4) |  | 66(46.2) | 59(23) | 2.09 | 1.05–4.16 | 0.03 |
  (3 + 2 + 1) |  | 77(53.8) | 198(77) | 1 |  |  |
Obstacles | ||||||
 Concerns about PrEP long-term effects on my health | 3.87 ± 1.01 |  |  |  |  |  |
  (5 + 4) |  | 99(69.2) | 225(87.5) | 0.38 | 0.11–1.29 | 0.12 |
  (3 + 2 + 1) |  | 44(30.7) | 32(12.5) | 1 |  |  |
 Concern about the fact that if I become infected by HIV, some ARV will no longer be efficient because they would have been taken as PrEP | 3.57 ± 1.06 |  |  |  |  |  |
  (5 + 4) |  | 78(54.5) | 151(58.7) | 0.47 | 0.11–1.91 | 0.29 |
  (3 + 2 + 1) |  | 65(45.5) | 106(41.3) | 1 |  |  |
 Concern about the fact that PrEP does not provide a complete protection against HIV | 3.78 ± 0.99 |  |  |  |  |  |
  (5 + 4) |  | 90(62.9) | 205(79.8) | 0.51 | 0.14–1.89 | 0.31 |
  (3 + 2 + 1) |  | 53(37.1) | 52(20.2) | 1 |  |  |
 Taking a drug every day | 3.53 ± 1.01 |  |  |  |  |  |
  (5 + 4) |  | 83(58.0) | 192(74.7) | 0.31 | 0.09–1.03 | 0.05 |
  (3 + 2 + 1) |  | 60(42.0) | 65(25.3) | 1 |  |  |
 Concern that taking PrEP could make me more likely to have sex without condom | 3.33 ± 0.96 |  |  |  |  |  |
  (5 + 4) |  | 78(54.5) | 140(54.5) | 0.77 | 0.17–3.45 | 0.73 |
  (3 + 2 + 1) |  | 65(45.5) | 117(45.5) | 1 |  |  |
 Concerns that having to take PrEP means that I put myself at risk for HIV | 2.97 ± 1.06 |  |  |  |  |  |
  (5 + 4) |  | 26(18.2) | 130(50.6) | 0.16 | 0.06–0.41 | 0.002 |
  (3 + 2 + 1) |  | 117(81.8) | 127(49.4) | 1 |  |  |
 PrEP could make my partners expect to have anal sex without condom with me | 3.47 ± 0.93 |  |  |  |  |  |
  (5 + 4) |  | 84(58.7) | 162(64) | 0.46 | 0.11–1.91 | 0.28 |
  (3 + 2 + 1) |  | 59(41.3) | 95(36) | 1 |  |  |
 Concerns that people will see me taking drug and will think I have HIV | 3.79 ± 1.01 |  |  |  |  |  |
  (5 + 4) |  | 88(61.5) | 220(85.6) | 0.33 | 0.14–0.77 | 0.01 |
  (3 + 2 + 1) |  | 55(38.5) | 37(14.4) | 1 |  |  |
 Concerns that people will see me taking drug and will want to know why I’m taking it | 3.67 ± 1.05 |  |  |  |  |  |
  (5 + 4) |  | 74(51.7) | 221(86.0) | 0.29 | 0.08–1.05 | 0.05 |
  (3 + 2 + 1) |  | 69(48.3) | 36(14.0) | 1 |  |  |
 Having to talk to my doctor about my sex life. | 2.89 ± 1.14 |  |  |  |  |  |
  (5 + 4) |  | 60(42.0) | 74(28.8) | 1.44 | 0.58–3.57 | 0.42 |
  (3 + 2 + 1) |  | 83(58.0) | 183(71.2) | 1 |  |  |
 Binding procedures for the drug procurement | 4.19 ± 0.79 |  |  |  |  |  |
  (5 + 4) |  | 117(81.8) | 245(95.3) | 0.34 | 0.12–0.93 | 0.03 |
  (3 + 2 + 1) |  | 26(18.2) | 12(4.7) | 1 |  |  |
 Size and Taste of drug | 3.81 ± 1.06 |  |  |  |  |  |
  (5 + 4) |  | 93(65.3) | 219(85.21) | 0.32 | 0.11–0.91 | 0.03 |
  (3 + 2 + 1) |  | 50(34.7) | 38(14.79) | 1 |  |  |
 Fee-paying drug | 4.27 ± 0.76 |  |  |  |  |  |
  (5 + 4) |  | 125(87.4) | 248(96.5) | 0.44 | 0.15–1.33 | 0.14 |
  (3 + 2 + 1) |  | 18(12.6) | 9(3.5) | 1 |  |  |
 Concern that PrEP may lead to prostitution | 3.5 ± 1.08 |  |  |  |  |  |
  (5 + 4) |  | 98(68.5) | 150(58.7) | 1.01 | 0.18–5.55 | 0.98 |
  (3 + 2 + 1) |  | 45(31.5) | 107(41.3) | 1 |  |  |
 Concern that PrEP might encourage to be unfaithful, | 3.49 ± 1.13 |  |  |  |  |  |
  (5 + 4) |  | 101(70.6) | 149(58.0) | 1.29 | 0.24–6.78 | 0.75 |
  (3 + 2 + 1) |  | 42(29.4) | 108(42.0) | 1 |  |  |
 Partner’s disagreement because I’m taking PrEP | 3.08 ± 1.11 |  |  |  |  |  |
  (5 + 4) |  | 54(37.8) | 138(53.7) | 0.28 | 0.06–1.27 | 0.10 |
  (3 + 2 + 1) |  | 89(62.2) | 119(46.3) | 1 |  |  |
 The unresponsive attitude of MSM community towards PrEP, | 3.39 ± 1.18 |  |  |  |  |  |
  (5 + 4) |  | 70(49.0) | 159(61.9) | 0.37 | 0.07–1.83 | 0.22 |
  (3 + 2 + 1) |  | 73(51.0) | 98(38.1) | 1 |  |  |
 PrEP as source of discrimination in health centers | 3.75 ± 0.99 |  |  |  |  |  |
  (5 + 4) |  | 93(65.0) | 214(83.3) | 0.41 | 0.10–1.74 | 0.23 |
  (3 + 2 + 1) |  | 50(34.0) | 43(16.7) | 1 |  |  |
 Concern that PrEP may increase risk-taking (e.g: increase in unprotected sex, number of sexual partners, etc) | 3.86 ± 0.96 |  |  |  |  |  |
  (5 + 4) |  | 89(62.2) | 227(88.3) | 0.36 | 0.12–1.12 | 0.07 |
  (3 + 2 + 1) |  | 54(37.8) | 30(11.7) | 1 |  |  |
 Concern that PrEP may increase the risk of contracting sexually transmitted infections other than HIV | 4 ± 0.99 |  |  |  |  |  |
  (5 + 4) |  | 101(70.6) | 230(89.5) | 0.55 | 0.14–2.09 | 0.38 |
  (3 + 2 + 1) |  | 42(29.4) | 27(10.5) | 1 |  |  |